Vivek Ra­maswamy’s My­ovant out­lines the PhII case for its lead drug, now in a late-stage test

When Vivek Ra­maswamy whipped up the biotech com­pa­ny My­ovant last year, he grabbed a late-stage drug called re­l­u­golix from Take­da as their lead ther­a­py. That drug helped win in­vestors over to a $218 mil­lion IPO — a record for 2016. And now My­ovant $MY­OV is lay­ing out some of Take­da’s mid-stage da­ta to demon­strate what the com­pa­ny hopes to see in the late-stage pro­gram.

The goal of re­l­u­golix is to re­duce heavy men­stru­al bleed­ing in women with uter­ine fi­broids. And that’s just what the high dose in the tri­al — the 40 mg dose be­ing stud­ied in Phase III — ac­com­plished. Look­ing to re­duce a score of at least 120 re­quired at study en­try to less than 10 from Week 6 through Week 12 on the Pic­to­r­i­al Blood Loss As­sess­ment Chart, or PBAC, 73% of the women on the 40 mg dose achieved a score of 0.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.